Drospirenone

CAS 67392-87-4 13 current recordsSmall Molecule

Who holds supplier records for Drospirenone? 13 organisations hold a current record for Drospirenone: an active US FDA Type II Drug Master File or a CEP. 10 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: Italy (3), India (3), China (2), Germany (1) and 4 other countries (4).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Drospirenone: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/drospirenone

Reading the evidence

  • 13 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 11 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Drospirenone expires 28 Jun 2031. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (13)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Drospirenone. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Drospirenone sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (10)

Certificates of Suitability on the EDQM register for Drospirenone, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 18 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
SYMBIOTEC PHARMALAB LIMITED IndoreIN
CEP 2018-118 - Rev 02
Drospirenone, Micronised, non-micronised
Apr 2026Inspected Mar 2026
Germany
TAPI NL B.V. AmsterdamNL
CEP 2010-014 - Rev 02
Drospirenone
Jul 2025—
INDUSTRIALE CHIMICA S.R.L. SaronnoIT
CEP 2022-506 - Rev 01
Drospirenone, Process 2
Jul 2025Inspected Oct 2025
Italy
STERLING CHEMICAL MALTA LTD. BirzebbugiaMT
CEP 2023-457 - Rev 00
Drospirenone, Code 202900
Jun 2025Inspected Apr 2025
Malta
GEDEON RICHTER PLC. BudapestHU
CEP 2024-461 - Rev 00
Drospirenone, Process I micronised
Jan 2025Inspected Jun 2026
Hungary
NEWCHEM S.p.A. MilanoIT
R1-CEP 2015-247 - Rev 01
Drospirenone, Micronised, non-micronised
Aug 2023—
BAYER AG LeverkusenDE
R1-CEP 2009-070 - Rev 02
Drospirenone, Micronised (micro 15)
Jul 2022—
CURIA SPAIN S.A.U. BoecilloES
R1-CEP 2012-049 - Rev 01
Drospirenone
Aug 2021—
ZHEJIANG XIANJU JUNYE PHARMACEUTICAL CO., LTD. XianjuCN
R1-CEP 2012-143 - Rev 00
Drospirenone
Nov 2018—
STERLING S.p.A. Solomeo Di CorcianoIT
R1-CEP 2009-193 - Rev 00
Drospirenone
Aug 2015—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (1 listed product contain Drospirenone). The latest listed patent expires 28 Jun 2031. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Drospirenone is a synthetic progestin used in oral contraceptive pills. It is characterized by its ability to mimic the natural hormone progesterone and also possesses anti-androgenic and slight anti-mineralocorticoid properties.

Chemical identity

IUPAC name
(1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione
Canonical SMILES
C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C
InChIKey
METQSPRSQINEEU-HXCATZOESA-N
Synonyms
Differin API, angeliq component drospirenone, beyaz component drospirenone, drsp, nextstellis component drospirenone, nsc-760103, safyral component drospirenone, slynd, yasmin component drospirenone, yaz component drospirenone, zk 30595, zk-30595

Therapeutic areas

ContraceptionHormone Replacement TherapyMenstrual Disorders

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Drospirenone?

13 organisations hold an active US FDA Type II Drug Master File or a CEP for Drospirenone: NEWCHEM SPA (Italy), Bayer AG (Germany), Gedeon Richter (Hungary), INDUSTRIALE CHIMICA SRL (Italy), STERLING SPA (Italy), SYMBIOTEC PHARMALAB PRIVATE LTD (India), TAPI NL BV (Netherlands) and Hubei Gedian Humanwell Pharmaceutical Co. Ltd (China), and 5 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Drospirenone Drug Master Files are active?

NEWCHEM SPA (DMF 22802, 36709), Bayer AG (DMF 12138), Gedeon Richter (DMF 17866), INDUSTRIALE CHIMICA SRL (DMF 41764, 20676), STERLING SPA (DMF 21733), SYMBIOTEC PHARMALAB PRIVATE LTD (DMF 32885), TAPI NL BV (DMF 22878) and Hubei Gedian Humanwell Pharmaceutical Co. Ltd (DMF 38856) and 2 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does Drospirenone have a European Certificate of Suitability?

Yes. 10 organisations hold a valid CEP for Drospirenone on the EDQM register, including SYMBIOTEC PHARMALAB LIMITED Indore (IN), TAPI NL B.V. Amsterdam (NL), INDUSTRIALE CHIMICA S.R.L. Saronno (IT), STERLING CHEMICAL MALTA LTD. Birzebbugia (MT), GEDEON RICHTER PLC. Budapest (HU) and NEWCHEM S.p.A. Milano (IT) and 4 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Drospirenone?

Yes. The latest patent listed for an approved US product containing Drospirenone expires 28 Jun 2031, across 1 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Drospirenone supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Drospirenone?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.